Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics bags $4M to advance cancer treatment

Viralytics bags $4M to advance cancer treatment

Following applications well in excess of A$10 million, Viralytics (ASX:VLA) has raised a total of $4 million via a share purchase plan to retail investors priced at $0.615 per share.

Viralytics stock was last trading at A$0.70, representing a 23% improvement over the past three months.

This is in addition to the successful placement that raised $28.4 million at the same price per share in December 2015.

That financing attracted a range of specialist healthcare investment funds, including a substantial commitment from OrbiMed Advisors, a new participant.

The funds from this capital raise will enable Viralytics to more rapidly advance its broad clinical program for CAVATAK, an oncolytic virus and the company’s lead product candidate.

CAVATAK is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers.

Intratumoural, intravenous and intravesicular delivery routes are also under investigation.

Two combination studies with checkpoint inhibitors are underway in late-stage melanoma patients.

The capital raise is interpreted as placing Viralytics in a position of financial security from which it can continue to build its clinical program while also increasing engagement with major pharmaceutical entities.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full VLA profile View Profile

Viralytics Timeline

Newswire
December 10 2015

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
lungs
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use